|
Exciting news for GE this month! The FDA has approved
General Electric's three-dimensional tomosynthesis breast cancer screening
technology. The approval means big opportunities for GE Digital X-Ray plant
which makes 3D images for the company's new digital mammography imaging machine
called SenoClaire. The plant is located in the Rensselaer Technology Park in
North Greenbush, NY, employs 135 people and is designed to produce several
thousand units annually.

Image
Credit
The new device is more effective than two-dimensional
breast cancer screenings because it helps clinicians uncover small cancers. The
new technology was tested at several medical centers, including Massachusetts
General Hospital. The technology employs a low-dose short X-ray sweep around
the positioned breast with nine exposures acquired using a "step-and-shoot"
method, removing the potential motion from the tube and helping to reduce blur
and increase image sharpness. "As a radiologist, it's important to offer
technology like this for patients that produces higher image quality without
increasing dose," said Dr. Murray Rebner MD, FACR, Professor of Diagnostic
Radiology and Molecular Imaging at Oakland University William Beaumont School
Of Medicine and Director of the Division of Breast Imaging and Intervention at
Beaumont Hospital, Royal Oak.
SenoClaire
is part of a breast cancer continuum which offers physicians and patients a
complete suite of solutions from screening and diagnosis through treatment and
monitoring. This machine, along with other solutions like contrast enhanced
spectral mammography, automated whole breast ultrasound, and molecular breast
imaging will equip healthcare providers with a comprehensive set of tools that
will help their patients.
According to Tom
Fiest, the general manager of North Greenbush Operation, the new technology
is compatible with many stenograph machines already in use and presents an
opportunity for hospitals and imaging centers to upgrade their cancer detection
technology.
|